Visionary Holdings Launches Medical-Grade Stem Cell Anti-Aging Products In Asia

Author: Benzinga Newsdesk | November 10, 2025 09:31am

Visionary Holdings Inc. ("GV" or the "Company"), a technology-driven multinational enterprise listed on Nasdaq (NASDAQ:GV), today announced that its wholly owned subsidiary, Visionary Health Technology Group Limited, has official launch of its medical-grade stem cell anti-aging product line, initially targeting the Chinese mainland and broader Asian markets.

This launch marks a major milestone following GV's entry into the stem cell and medical aesthetics sector earlier this year, as well as its strategic partnership and global technology licensing agreement with Jiangsu Yike Regenerative Medicine Co., Ltd. ("Yike"), advancing the Company's commercialization in regenerative medicine.

Core Product Lines and Innovative Value Model

GV's anti-aging product portfolio includes three major categories:

• Comprehensive Regenerative Package — the flagship Life Rejuvenation Program, combining mesenchymal stem cells, NK cell therapy, and AI-based diagnostics, designed for entrepreneurs and high-net-worth individuals.
• Precision Repair Package — integrating targeted stem cell therapy and DFPP blood purification for clients with specific degenerative or chronic conditions.
• Premium Personalized Program — including full-genome sequencing, dual-institution medical consultations, and annual customized health management for ultra-high-net-worth clients.

This product launch marks GV's next operational milestone following its global licensing agreement with Yike, transitioning from R&D collaboration to tangible market implementation. GV has integrated Yike's proprietary regenerative technologies into a full suite of personalized anti-aging and cellular rejuvenation solutions, covering stem cell therapy, NK cell revitalization, AI-based health assessment, and nano-delivery systems.

The new products will be operated through GV's Asia-Pacific headquarters in Hong Kong, initially launching across Hong Kong, Singapore, and the Chinese mainland to provide premium, customized health solutions for high-end clients.

GV plans to advance its commercialization strategy through the following initiatives:

• Establish a joint venture production and clinical application base to enable localized manufacturing and validation of stem cell products;
• Build a cross-border sales and distribution network covering mainland China, Hong Kong, and Southeast Asia, while expanding into Canada, the United States, and Mexico;
  
  
  
  Partner with premium medical and aesthetic institutions to jointly develop branded clinics and anti-aging experience center

Posted In: GV